Publication
HHS delegates exclusion authority to CMS
HHS Secretary Robert F. Kennedy Jr. announced that the CMS would exercise exclusion authority to remove “bad actors” from federal healthcare programs “effective immediately.”
Global | Publication | July 2026
Fujifilm had brought infringement proceedings against several German entities in the Kodak group, alleging infringement of European Patent EP 3 511 174. The Local Division Mannheim upheld the patent in amended form and found infringement not only in Germany but also in the United Kingdom.
This first-instance decision had already attracted considerable attention, as it was among the first judgments in which the UPC granted injunctive relief with effect extending to a non-UPC state.
In its decision of 2 June 2026 (Case Nos. UPC_CoA_312/2025, UPC_CoA_880/2025, UPC_CoA_333/2025, UPC_CoA_882/2025), the Court of Appeal overturned the finding of infringement. At the same time, however, it confirmed the UPC’s jurisdiction to adjudicate patent infringement claims relating to the UK designation of the European patent, thereby significantly strengthening the possibility of cross-border patent enforcement before the UPC.
Article 34 UPCA does not limit international jurisdiction
At the heart of the Court of Appeal’s decision lies its interpretation of Article 34, Unified Patent Court Agreement (UPCA). Kodak argued that this provision limits the UPC’s jurisdiction to the territories of the Contracting Member States of the Agreement. The Court of Appeal expressly rejected this view. In its assessment, Article 34 UPCA governs only the territorial scope and effect of UPC decisions, not the Court’s international jurisdiction. Instead, jurisdiction must be determined in accordance with the Brussels Ia Regulation, which provides for the general jurisdiction of the courts at the defendant’s domicile. Where the defendant is domiciled in a UPC Contracting Member State - as was the case for Kodak’s German entities - the UPC may, in principle, also adjudicate infringement claims relating to national parts of a European patent outside the UPC territory (CJEU, Case C 339/22 – BSH Hausgeräte v. Electrolux – see CJEU reference: International jurisdiction and liability at the intersection of patent law and product safety law).
In doing so, the Court of Appeal goes a step further than earlier UPC decisions and makes clear that it does not regard the UPC as a regionally confined specialised court. Rather, it views the UPC as a fully-fledged court of a community of Member States, required to apply the jurisdictional rules of European civil procedure law in the same manner as national courts.
Particularly noteworthy is the Court’s finding that, once jurisdiction has been established, the UPC may not decline to exercise it on the ground that a foreign court would be a more appropriate forum for resolving the dispute. According to the Court of Appeal, the common law doctrine of forum non conveniens has no place within the framework of the Brussels Ia Regulation. Where jurisdiction exists based on the defendant’s domicile, the UPC is obliged to exercise that jurisdiction.
Exercising international jurisdiction in accordance with the principle of international comity
This, however, did not fully resolve the question of how far the UPC’s adjudicative powers extend on the merits. The central challenge of cross-border patent litigation lies in the fact that questions of patent validity remain subject to the exclusive jurisdiction of the respective national courts of third countries. To address this tension, the Court of Appeal developed a nuanced procedural framework based on the principle of international comity.
Under this approach, the UPC is required to exercise its international jurisdiction while, at the same time, avoiding conflicts with the sovereign rights of other states. In doing so, the Court must apply the law governing the patent right in question.
For national designations of a European patent outside the UPC territory, the Court of Appeal considers decisions on validity to remain, in principle, the responsibility of the competent national courts. At the same time, following the reasoning of the CJEU in BSH v. Electrolux, the UPC should not be compelled to dismiss every cross-border infringement action merely because a validity challenge has been raised.
Instead, the Court has established a graduated framework that provides for different procedural solutions depending on the territories concerned and the status of parallel validity proceedings:
The Court of Appeal’s clarification of the UPC’s international jurisdiction beyond the territory of the UPC Contracting Member States – and even beyond the European Union – is likely to lead to an increase in cross-border patent litigation. The prospect of bringing a single action that covers not only the UPC territory but also commercially important jurisdictions, such as the United Kingdom, Switzerland and Spain, is highly attractive to patent proprietors. Such a pan-European action can exert considerable pressure on defendants and thereby strengthen a claimant’s negotiating position in settlement discussions. After all, facilitating streamlined enforcement without the need to fragment disputes into multiple national proceedings with potentially divergent outcomes was one of the key objectives underlying the creation of the UPC.
At the same time, litigation spanning several non-UPC jurisdictions may, despite being decided by a single chamber, quickly develop into complex and potentially unmanageable proceedings. Difficulties arise where issues must be determined under different national legal systems, or where the validity of the European patent is uncertain and may be assessed differently from one jurisdiction to another. Such circumstances can result in significant delays and substantial litigation costs. In some cases, a more focused and streamlined action may therefore prove strategically preferable, delivering quicker results while still providing a strong basis for settlement negotiations.
Publication
HHS Secretary Robert F. Kennedy Jr. announced that the CMS would exercise exclusion authority to remove “bad actors” from federal healthcare programs “effective immediately.”
Publication
Now in its seventh year, our annual English Premier League (EPL) football report, Keeping Possession, captures insights from our global sports law team on the key trends and topics shaping the landscape of English football.
Subscribe and stay up to date with the latest legal news, information and events . . .
© Norton Rose Fulbright LLP 2026